|Bid||11.84 x 10041900|
|Ask||10.68 x 831100|
|Day's range||11.23 - 11.48|
|52-week range||8.26 - 11.49|
|PE ratio (TTM)||45.69|
|Forward dividend & yield||0.10 (1.32%)|
|1y target est||8.53|
Resmed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.
ResMed (RMD) achieves strong global revenue growth for the past few quarters on the back of sales of sleep devices, respiratory care devices, mask systems and software solutions.
NEW YORK, Dec. 01, 2017-- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ...
ResMed (RMD) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) may face issues if the North American Free Trade Agreement is re-negotiated.
Macquarie Group Ltd (ASX:MQG) manages the Macquarie High Conviction Fund. This is the fund which they describe as "a concentrated portfolio of only our most compelling stock ideas"
Fisher & Paykel Healthcare has won a patent case against rival medical products manufacturer ResMed, after a court in the United Kingdom ruled the patent claim invalid. In 2016, New Zealand-based Fisher & Paykel sought a declaration from the High Court that three of ResMed's European patents were invalid in the UK and should be revoked. ResMed revoked two of its patents in the UK just before the trial was due to start, but left one for consideration by the High Court's patents division.
Shares in battled pharmaceutical company Mayne Pharma Group Ltd (ASX:MYX) rise on the back of positive announcements from rivals Teva and Mylan.
A new range of sleep apnoea masks has helped lift respiratory device maker ResMed's first quarter sales revenue 13 per cent to $US523.7 million ($A683.7 million). The dual-listed company's ASX shares have jumped on the strong quarterly update and were trading 5.7 per cent higher at $10.73 by 1214 AEDT. ResMed chief executive Mick Farrell said product innovation was helping the company improve its market share.
On a per-share basis, the San Diego-based company said it had net income of 60 cents. Earnings, adjusted for amortization costs, came to 66 cents per share. The results topped Wall Street expectations. ...
Investors are concerned about the Medical sector that saw a lot of struggle during the first nine months of the year, thanks to the political change and the ongoing policy-restructuring related battle.
LAS VEGAS, Jan. 6, 2017 /PRNewswire/ -- The world is about to find out how well it really sleeps - and how to sleep better - thanks to SleepScore Labs, a new company focused on helping people understand ...
- World's largest repository of sleep data - a giant step forward for sleep medicine - Predictive analytics from data will improve therapy and outcomes for sleep patients - Milestone reinforces ResMed's ...
SAN DIEGO, Dec. 20, 2016 /PRNewswire/ -- ResMed (NYSE: RMD) today announced that industry leader Carlos M. Nunez, MD, will become ResMed's chief medical officer, effective January 3, 2017. Nunez most recently ...
SAN DIEGO, Dec. 19, 2016 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced it will report its second quarter of fiscal year 2017 results on Monday, January 23, 2017 after the New York Stock Exchange ...